Synthesis and Pharmacological Properties of the Azo-Conjugate of Erythropoietin β with Poly(Ethylene Glycol)

被引：0
作者：
Sheremet'ev, S., V [1 ]
Lonshakov, D., V [1 ]
Belosludtseva, E. M. [1 ]
Borisova, O., V [2 ]
Sidorova, A., V [1 ]
Kalinskii, A., V [1 ]
机构：
[1] FORT LLC, Okskoe 390540, Ryazan Region, Russia
[2] II Mechnikov Inst Vaccines & Sera, 5a Malyi Kazennyi Pereulok, Moscow 105064, Russia
来源：
PHARMACEUTICAL CHEMISTRY JOURNAL | 2021年 / 55卷 / 07期
关键词：
PEGylated proteins; azo coupling; erythropoietin beta; Mircera; pharmacokinetics; bioequivalence; POLYETHYLENE-GLYCOL; ANEMIA; DISEASE; PEGYLATION; DIALYSIS; IRON;
D O I：
10.1007/s11094-021-02480-3
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A conjugate of erythropoietin beta with 30 kDa linear methoxy poly(ethylene glycol) characterized by the presence of an azo spacer between the protein fragment and poly(ethylene glycol) was developed for import-substitution of Mircera drug in the Russian Federation. The erythropoietic activity of the synthesized conjugate was determined. Its pharmacokinetics in CBA mice were found to be comparable to those of Mircera. The bioequivalence of the proposed azo conjugate and Mircera was established based on the calculated drug pharmacokinetic parameters in mice.
引用
收藏
页码：698 / 705
页数：8
相关论文
共 42 条
  • [1] [Anonymous], 2005, HDB EXPT PRECLINICAL
  • [2] [Anonymous], 2014, European Pharmacopoeia, V8th
  • [3] [Anonymous], 2013, HDB DRUG REV, VIV
  • [4] Balthasar JP, 1999, AM J PHARM EDUC, V63, P194
  • [5] A NEW PROCEDURE FOR THE SYNTHESIS OF POLYETHYLENE GLYCOL-PROTEIN ADDUCTS - EFFECTS ON FUNCTION, RECEPTOR RECOGNITION, AND CLEARANCE OF SUPEROXIDE-DISMUTASE, LACTOFERRIN, AND ALPHA-2-MACROGLOBULIN
    BEAUCHAMP, CO
    GONIAS, SL
    MENAPACE, DP
    PIZZO, SV
    [J]. ANALYTICAL BIOCHEMISTRY, 1983, 131 (01) : 25 - 33
  • [6] Buemi M., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P299, DOI 10.2174/187152506778520754
  • [7] Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury
    Cai, ZQ
    Manalo, DJ
    Wei, G
    Rodriguez, ER
    Fox-Talbot, K
    Lu, HS
    Zweier, JL
    Semenza, GL
    [J]. CIRCULATION, 2003, 108 (01) : 79 - 85
  • [8] Intravenous CERA maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study
    Canaud, Bernard
    Mingardi, Giulio
    Braun, Johann
    Aljama, Pedro
    Kerr, Peter G.
    Locatelli, Francesco
    Villa, Giuseppe
    Van Vlem, Bruno
    McMahon, Alan W.
    Kerloeguen, Cecile
    Beyer, Ulrich
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (11) : 3654 - 3661
  • [9] Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes
    Collins, AJ
    Brenner, RM
    Ofman, JJ
    Chi, EM
    Stuccio-White, N
    Krishnan, M
    Solid, C
    Ofsthun, NJ
    Lazarus, JM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (03) : 481 - 488
  • [10] Continuous Erythropoietin Receptor Activator (CERA) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study
    De Francisco, A. L. M.
    Sulowicz, W.
    Klinger, M.
    Niemczyk, S.
    Vargemezis, V.
    Metivier, F.
    Dougherty, F. C.
    Oguey, D.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (12) : 1687 - 1696
12345